DWP 820S006
Alternative Names: DWP820S006Latest Information Update: 28 Jul 2024
At a glance
- Originator Daewoong Pharmaceutical
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spinal cord injuries
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Spinal-cord-injuries in South Korea (Parenteral)
- 12 Jun 2020 Preclinical trials in Spinal cord injuries in South Korea (Parenteral), prior to June 2020 (Daewoong Pharmaceutical pipeline, June 2020)